RecruitingNCT02285582

International Rare Histiocytic Disorders Registry (IRHDR)

Studying Erdheim-Chester disease

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: The Hospital for Sick Children
Principal Investigator: Oussama Abla, MD, M.D
The Hospital for Sick Children
Intervention: Registry study(other)
Enrollment: 400 enrolled
Eligibility: All sexes
Timeline: 2014 – 2028

Study locations (15)

The University of Alabama at Birmingham, Birmingham, Alabama, United States
Children's Hospital of Los Angeles, Los Angeles, California, United States
Valley Children's Hospital, Madera, California, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Hospital Nacional de Pediatria Garrahan, Buenos Aires, Argentina
The Hospital for Sick Children, Toronto, Ontario, Canada
Centre hospitalier universitaire Sainte-Justine, Montreal, Quebec, Canada
University Hospital Brno, Brno, Czechia
Rostock University Medical Hospital, Rostock, Germany
Azienda Ospedaliero-Universitaria Meyer, Florence, Italy
Prinses Maxima Center, Utrecht, CS, Netherlands
Children's Memorial Health Institute, Warsaw, Poland
Hospital Universitario Cruces, Barakaldo, Spain

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02285582 on ClinicalTrials.gov

Other trials for Erdheim-Chester disease

Additional recruiting or active studies for the same condition.

See all trials for Erdheim-Chester disease →

← Back to all trials